Stem definition | Drug id | CAS RN |
---|---|---|
immunomodulators, both stimulant/suppressive and stimulant | 5383 | 1306760-87-1 |
Dose | Unit | Route |
---|---|---|
0.92 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
May 20, 2020 | EMA | Bristol-Myers Squibb Pharma EEIG | |
March 25, 2020 | FDA | CELGENE INTL |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple sclerosis relapse | 177.69 | 40.63 | 71 | 2587 | 44782 | 53301626 |
Fatigue | 130.30 | 40.63 | 169 | 2489 | 730337 | 52616071 |
Headache | 87.02 | 40.63 | 119 | 2539 | 536702 | 52809706 |
Dizziness | 66.91 | 40.63 | 87 | 2571 | 372172 | 52974236 |
COVID-19 | 61.44 | 40.63 | 32 | 2626 | 36856 | 53309552 |
COVID-19 pneumonia | 52.89 | 40.63 | 18 | 2640 | 7185 | 53339223 |
Unevaluable event | 50.09 | 40.63 | 31 | 2627 | 49467 | 53296941 |
Multiple sclerosis | 43.61 | 40.63 | 23 | 2635 | 27130 | 53319278 |
Balance disorder | 43.49 | 40.63 | 33 | 2625 | 73174 | 53273234 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
COVID-19 | 50.04 | 45.57 | 19 | 514 | 31996 | 32480997 |
Multiple sclerosis relapse | 46.34 | 45.57 | 14 | 519 | 11767 | 32501226 |
Source | Code | Description |
---|---|---|
ATC | L04AA38 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007166 | Immunosuppressive Agents |
MeSH PA | D000081243 | Sphingosine 1 Phosphate Receptor Modulators |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Multiple sclerosis | indication | 24700007 | DOID:2377 |
Preinfarction syndrome | contraindication | 4557003 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Mobitz type II atrioventricular block | contraindication | 28189009 | DOID:11312 |
Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
Sinoatrial block | contraindication | 65778007 | |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Cerebrovascular accident | contraindication | 230690007 | |
Transient ischemic attack | contraindication | 266257000 | DOID:224 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.46 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 0.23MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 8481573 | May 14, 2029 | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS |
EQ 0.23MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 9382217 | May 14, 2029 | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS |
EQ 0.46MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 8481573 | May 14, 2029 | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS |
EQ 0.46MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 9382217 | May 14, 2029 | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS |
EQ 0.92MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 8481573 | May 14, 2029 | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS |
EQ 0.92MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 9382217 | May 14, 2029 | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS |
EQ 0.23MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 10239846 | Nov. 15, 2030 | INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
EQ 0.46MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 10239846 | Nov. 15, 2030 | INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
EQ 0.92MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | 10239846 | Nov. 15, 2030 | INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 0.23MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | May 27, 2024 | FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS |
EQ 0.46MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | May 27, 2024 | FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS |
EQ 0.92MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | May 27, 2024 | FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS |
EQ 0.23MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | March 25, 2025 | NEW CHEMICAL ENTITY |
EQ 0.46MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | March 25, 2025 | NEW CHEMICAL ENTITY |
EQ 0.92MG BASE | ZEPOSIA | CELGENE INTL | N209899 | March 25, 2020 | RX | CAPSULE | ORAL | March 25, 2025 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sphingosine 1-phosphate receptor 1 | GPCR | AGONIST | EC50 | 9.39 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Sphingosine 1-phosphate receptor 5 | GPCR | AGONIST | EC50 | 7.96 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Sphingosine 1-phosphate receptor 4 | GPCR | EC50 | 5.38 | CHEMBL | |||||
Sphingosine 1-phosphate receptor 3 | GPCR | EC50 | 5 | CHEMBL | |||||
Sphingosine 1-phosphate receptor 2 | GPCR | EC50 | 5.02 | CHEMBL |
ID | Source |
---|---|
Z80293URPV | UNII |
1618636-37-5 | SECONDARY_CAS_RN |
4039423 | VANDF |
4039424 | VANDF |
C4278675 | UMLSCUI |
JEU | PDB_CHEM_ID |
CHEMBL3707247 | ChEMBL_ID |
52938427 | PUBCHEM_CID |
DB12612 | DRUGBANK_ID |
CHEMBL3707246 | ChEMBL_ID |
C000607776 | MESH_SUPPLEMENTAL_RECORD_UI |
D10968 | KEGG_DRUG |
8709 | IUPHAR_LIGAND_ID |
10057 | INN_ID |
2288235 | RXNORM |
870525003 | SNOMEDCT_US |
871794001 | SNOMEDCT_US |
871800005 | SNOMEDCT_US |
38279 | MMSL |
d09534 | MMSL |
018313 | NDDF |
018314 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ZEPOSIA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-820 | CAPSULE | 0.92 mg | ORAL | NDA | 29 sections |